Study Summary
The purpose of this clinical trial is to evaluate the safety and efficacy of CAR1922T2 T-cell therapy in participants with relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Participants will receive a single infusion of CAR1922T2 T-cells and complete follow-ups over the next three years.
Want to learn more about this trial?
Request More InfoInterventions
CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）BIOLOGICAL
Administer a single infusion of CAR1922T2 T cells to this group of patients following fludarabine plus cyclophosphamide (F+C) lymphodepletion
Study Locations
No locations listed.